Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today the U.S. Food and Drug Administration (FDA) has set a new meeting date of November 30, 2015, to review the...
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that contracted revenue from its 2016 Turkish Ministry of Health (MOH) order alone is expected to be approximately...
Guided Therapeutics, Inc. (OTCQB:GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it is now negotiating with three groups for rights to sell LuViva in China and other Asian markets. The...
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it expects to ship 25 LuViva® Advance Cervical Scan units and approximately 40,000 single-patient-use...
Results of a study presented at a major international women’s health conference indicate that the LuViva® Advanced Cervical Scan was able predict which women would progress from mild cervical abnormalities to more severe forms of the disease that require treatment....
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has shipped the first four LuViva® Advance Cervical Scan units to its Turkish distributor for its order...
